CVintra # CVinter # CVtotal [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2008-11-29 11:14 (6401 d 19:55 ago) – Posting: # 2833
Views: 9,010

Dear Muneesh,

❝ Case-1: [...] intra-subject CV of 0.5363 and observed %T/R ratio of 0.9148. The sample size calculated is 175 for two-way cross-over pivotal study as programmed.


OK, confirmed your calculations (actually 176...) in two programs.

❝ I want to use the replicate (four-way cross-over) study design,


Why?

❝ in that case can I do the pivotal four-way cross-over study with at least half the number of subjects i.e. 88?


Yes, but you should:

❝ Case-2: […] parallel design […] total CV of 0.16 and observed %T/R ratio of 112.08. The sample size calculated is 27 for two-way cross-over study as programmed. In that case can I do the pivotal parallel study with at least double the number of subjects i.e. 54?


What? Your sample size is 27 per group in parallel study (no X-over!), or 54 in total. Remember: in a parallel design, any differences in the two groups will be treated as a treatment effect - be cautious!

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
213 visitors (0 registered, 213 guests [including 16 identified bots]).
Forum time: 08:09 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5